Doctors want to improve state drug-tracking system
A study has found that most doctors in Indiana aren't frequently using an electronic system designed to detect prescription drug abuse.
A study has found that most doctors in Indiana aren't frequently using an electronic system designed to detect prescription drug abuse.
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
When the next enrollment season opens for the Obamacare exchange in Indiana, more than half the “health insurers” will actually be doctors and hospitals.
The senators planned to submit a letter Thursday to Acting Secretary Sloan Gibson requesting a review of Indiana facilities after a May 20 request to former Secretary Eric Shinseki went unanswered. Shinseki resigned last week.
A government document provided to The Associated Press indicates that at least 2 million people enrolled for taxpayer-subsidized private health insurance have data discrepancies in their applications.
Indiana will receive part of the settlement money. The accord will prohibit Glaxo from providing incentive payments to salespeople that encourage uses of the drugs not indicated on their labels.
The Department of Veterans Affairs maintained 10 such "secret waiting lists" of military veterans in need of care at facilities in Kansas, Missouri, Illinois and Indiana, the letters said.
A bill proposed by four Senate Republicans would give veterans more flexibility to see a private doctor if they are forced to wait too long for an appointment at a Veterans Affairs hospital or clinic.
Veterans Affairs Secretary Eric Shinseki resigned Friday after publicly apologizing for systemic problems plaguing the agency's health care system.
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
A report found the VA’s Eastern Area Fiduciary Hub in Indianapolis was “not timely processing allegations of misuse of beneficiary funds, conducting field examinations, and processing some incoming mail.”
Getting everyone into the same room prior to surgeries is cutting costs and improving health.
The 5-year-old firm has pledged to invest $20 million to double the size of its corporate headquarters in Indianapolis and lease real estate for a series of 3,500-square-foot health clinics across the state.
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
A judge has sentenced an Indianapolis doctor to 10 years in prison for writing illicit prescriptions for powerful painkillers after the Drug Enforcement Administration had suspended his authority to dispense controlled substances.
U.S. Sen. Joe Donnelly said administrators at Indiana's VA hospitals have told him they don't have the same kind of problems as the 26 veterans facilities across the country facing complaints about long waits and backlogs.
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
Two public hearings are scheduled this week on Gov. Mike Pence's plan to use Medicaid funds to expand the Healthy Indiana Plan to provide insurance under the federal health care overhaul.
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.